IL284050A - פיראזולופירימידינים מותמרים ופורינים מותמרים והשימוש בהם כמעכבי 1 uso - Google Patents
פיראזולופירימידינים מותמרים ופורינים מותמרים והשימוש בהם כמעכבי 1 usoInfo
- Publication number
- IL284050A IL284050A IL284050A IL28405021A IL284050A IL 284050 A IL284050 A IL 284050A IL 284050 A IL284050 A IL 284050A IL 28405021 A IL28405021 A IL 28405021A IL 284050 A IL284050 A IL 284050A
- Authority
- IL
- Israel
- Prior art keywords
- substituted
- pyrazolopyrimes
- usp1
- inhibitors
- ubiquitin specific
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783014P | 2018-12-20 | 2018-12-20 | |
| US201962799423P | 2019-01-31 | 2019-01-31 | |
| US201962857986P | 2019-06-06 | 2019-06-06 | |
| US201962868616P | 2019-06-28 | 2019-06-28 | |
| US201962946263P | 2019-12-10 | 2019-12-10 | |
| PCT/US2019/067521 WO2020132269A1 (en) | 2018-12-20 | 2019-12-19 | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL284050A true IL284050A (he) | 2021-08-31 |
Family
ID=71100912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL284050A IL284050A (he) | 2018-12-20 | 2021-06-15 | פיראזולופירימידינים מותמרים ופורינים מותמרים והשימוש בהם כמעכבי 1 uso |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11485736B2 (he) |
| EP (1) | EP3897652A4 (he) |
| JP (1) | JP2022511515A (he) |
| KR (1) | KR20210105887A (he) |
| CN (1) | CN113164485A (he) |
| AU (1) | AU2019405925A1 (he) |
| BR (1) | BR112021010715A2 (he) |
| CA (1) | CA3122108A1 (he) |
| CL (1) | CL2021001575A1 (he) |
| CO (1) | CO2021009078A2 (he) |
| IL (1) | IL284050A (he) |
| MX (1) | MX2021007179A (he) |
| SG (1) | SG11202106232TA (he) |
| TW (2) | TWI834784B (he) |
| WO (1) | WO2020132269A1 (he) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3005353A1 (en) | 2015-11-20 | 2017-05-26 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| WO2020132269A1 (en) | 2018-12-20 | 2020-06-25 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
| US20230065636A1 (en) * | 2020-01-15 | 2023-03-02 | KSQ Therapeutics, Inc. | Compositions of substituted pyrazolopyrimidines and uses thereof |
| IL295149A (he) * | 2020-02-14 | 2022-09-01 | Ksq Therapeutics Inc | שילובים טיפוליים המכילים מעכבי פרוטיאז 1 מעבד ספציפי ליוביקוויטין (usp1) ומעכבי פולי (adp-ריבוז) פולימראז (parp) |
| US20230219965A1 (en) * | 2020-06-02 | 2023-07-13 | KSQ Therapeutics, Inc. | Nitrogen-containing fused bicyclic compounds and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
| CA3196564A1 (en) * | 2020-10-30 | 2022-05-05 | Hanlan Liu | Solid state forms of substituted pyrazolopyrimidines and uses thereof |
| US20240182481A1 (en) * | 2021-02-15 | 2024-06-06 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
| WO2022197892A1 (en) * | 2021-03-17 | 2022-09-22 | Tango Therapeutics, Inc. | Purine derivatives as anticancer agents |
| EP4319758A1 (en) * | 2021-04-07 | 2024-02-14 | Forma Therapeutics, Inc. | Inhibiting ubiquitin-specific protease 1 (usp1) |
| WO2022233263A1 (zh) * | 2021-05-03 | 2022-11-10 | 山东轩竹医药科技有限公司 | 三并环类泛素特异性蛋白酶1抑制剂及其用途 |
| WO2022253188A1 (en) * | 2021-05-31 | 2022-12-08 | Impact Therapeutics (Shanghai) , Inc | Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof |
| GB202114863D0 (en) | 2021-10-18 | 2021-12-01 | Syngenta Crop Protection Ag | Improvements in or relating to organic compounds |
| CA3235663A1 (en) * | 2021-10-19 | 2023-04-27 | Impact Therapeutics (Shanghai), Inc. | Substituted triazoloheteroaryl compounds as usp1 inhibitors and the use thereof |
| CN114031556B (zh) * | 2021-11-08 | 2023-03-31 | 温州大学 | 一种绿色的一锅法制备5-氨基-n-芳基-3-芳基吡唑类化合物的合成方法 |
| WO2023083286A1 (en) * | 2021-11-12 | 2023-05-19 | Insilico Medicine Ip Limited | Small molecule inhibitors of ubiquitin specific protease 1 (usp1) and uses thereof |
| PE20241350A1 (es) * | 2021-11-12 | 2024-07-03 | Insilico Medicine Ip Ltd | Inhibidores de moleculas pequenas de la proteasa especifica de ubiquitina 1 (usp1) y sus usos |
| CN114181237B (zh) * | 2021-12-01 | 2024-02-23 | 上海凌凯医药科技有限公司 | 一种1-异丙基吡唑-5-硼酸频那醇酯的合成方法 |
| CN118369094A (zh) * | 2021-12-09 | 2024-07-19 | Ksq治疗公司 | 制备取代的吡唑并嘧啶的方法 |
| CN118525022A (zh) * | 2022-01-27 | 2024-08-20 | 西藏海思科制药有限公司 | 一种氮杂并环衍生物及其在医药上的应用 |
| WO2023148643A1 (en) * | 2022-02-03 | 2023-08-10 | Aurigene Oncology Limited | Fused bicyclic heterocyclyl compounds as usp1 inhibitors |
| CN118715012A (zh) * | 2022-02-18 | 2024-09-27 | 西藏海思科制药有限公司 | 一种吡唑并吡啶衍生物及其在医药上的应用 |
| WO2023196955A1 (en) * | 2022-04-08 | 2023-10-12 | KSQ Therapeutics, Inc. | Therapeutic combinations comprising ubiquitin- specific-processing protease 1 (usp1) inhibitors and chemotherapy agents |
| WO2023208130A1 (zh) * | 2022-04-29 | 2023-11-02 | 江苏亚虹医药科技股份有限公司 | 嘧啶类化合物、其制备方法及其医药用途 |
| WO2023250084A1 (en) * | 2022-06-23 | 2023-12-28 | Forma Therapeutics, Inc. | Usp1 inhibitors and uses thereof |
| US20240092779A1 (en) * | 2022-06-29 | 2024-03-21 | Zentaur Therapeutics Usa Inc. | Usp1 inhibitors and uses thereof |
| WO2024022266A1 (en) * | 2022-07-25 | 2024-02-01 | Guangdong Newopp Biopharmaceuticals Co., Ltd. | Heteroaryl compounds as inhibitors of usp1 |
| WO2024022519A1 (zh) * | 2022-07-28 | 2024-02-01 | 先声再明医药有限公司 | 杂环并嘧啶类化合物及其应用 |
| WO2024032647A1 (zh) * | 2022-08-09 | 2024-02-15 | 上海济煜医药科技有限公司 | 含氮杂环化合物作为泛素-特异性蛋白酶1抑制剂的制备方法、应用及其用途 |
| WO2024041634A1 (zh) * | 2022-08-26 | 2024-02-29 | 先声再明医药有限公司 | 三环类化合物及其应用 |
| TW202410891A (zh) * | 2022-09-02 | 2024-03-16 | 大陸商上海齊魯製藥研究中心有限公司 | 泛素特異性蛋白酶1抑制劑 |
| TW202411231A (zh) * | 2022-09-09 | 2024-03-16 | 大陸商正大天晴藥業集團股份有限公司 | 用作泛素-特異性蛋白酶抑制劑的取代嘌呤酮衍生物 |
| WO2024061213A1 (zh) * | 2022-09-20 | 2024-03-28 | 正大天晴药业集团股份有限公司 | 用作泛素-特异性蛋白酶抑制剂的羰基稠合杂环衍生物 |
| WO2024078436A1 (zh) * | 2022-10-09 | 2024-04-18 | 海南先声再明医药股份有限公司 | 杂环并嘧啶类化合物、药物组合物及其应用 |
| WO2024086790A1 (en) | 2022-10-21 | 2024-04-25 | Exelixis, Inc. | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-c]PYRIDINE COMPOUNDS AND DERIVATIVES AS USP1 INHIBITORS |
| TW202425982A (zh) * | 2022-11-04 | 2024-07-01 | 大陸商深圳晶泰科技有限公司 | 泛素特異性蛋白酶1的抑制劑及其應用 |
| WO2024149675A1 (en) | 2023-01-12 | 2024-07-18 | Syngenta Crop Protection Ag | Herbicidal imidazole compounds |
| WO2024153250A1 (zh) * | 2023-01-20 | 2024-07-25 | 杭州英创医药科技有限公司 | 作为usp1抑制剂的化合物 |
| CN116768906B (zh) * | 2023-05-29 | 2024-04-09 | 遵义医科大学珠海校区 | 一种三并环化合物及其制备方法和应用 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5010175A (en) | 1988-05-02 | 1991-04-23 | The Regents Of The University Of California | General method for producing and selecting peptides with specific properties |
| EP1493825A3 (en) | 1990-06-11 | 2005-02-09 | Gilead Sciences, Inc. | Method for producing nucleic acid ligands |
| AU672790B2 (en) | 1992-07-15 | 1996-10-17 | Novartis Ag | Variants of parathyroid hormone and its fragments |
| WO1996023899A1 (en) | 1995-02-01 | 1996-08-08 | University Of Massachusetts Medical Center | Methods of selecting a random peptide that binds to a target protein |
| JP2001512560A (ja) | 1996-10-08 | 2001-08-21 | ユー―ビスイス ベスローテン フェンノートシャップ | 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段 |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
| US7754463B2 (en) | 2006-06-20 | 2010-07-13 | Dana-Farber Cancer Institute | Inhibitors of USP1 Deubiquitinating Enzyme Complex |
| CA2703006A1 (en) | 2006-10-20 | 2008-06-05 | Dana-Farber Cancer Institute | Compositions and methods for treating cancer |
| US7964356B2 (en) | 2007-01-16 | 2011-06-21 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| BRPI0817503B8 (pt) | 2007-10-05 | 2021-05-25 | Sstarbio Pte Ltd | derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa |
| KR20100126467A (ko) * | 2008-03-03 | 2010-12-01 | 타이거 파마테크 | 티로신 키나아제 억제제 |
| WO2009157196A1 (ja) * | 2008-06-25 | 2009-12-30 | 武田薬品工業株式会社 | アミド化合物 |
| GB0917934D0 (en) * | 2009-10-13 | 2009-11-25 | Syngenta Ltd | Herbicidal compounds |
| WO2011137320A2 (en) | 2010-04-30 | 2011-11-03 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibitors of usp1 deubiquitinating enzyme activity |
| CA2896731A1 (en) | 2012-12-28 | 2014-07-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof |
| EP3375877A1 (en) | 2013-11-18 | 2018-09-19 | Crispr Therapeutics AG | Crispr-cas system materials and methods |
| KR101766194B1 (ko) * | 2015-08-07 | 2017-08-10 | 한국과학기술연구원 | RET 키나아제 저해제인 신규 3-(이속사졸-3-일)-피라졸로[3,4-d]피리미딘-4-아민 화합물 |
| CA3005353A1 (en) | 2015-11-20 | 2017-05-26 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| WO2020132269A1 (en) | 2018-12-20 | 2020-06-25 | KSQ Therapeutics, Inc. | Substituted pyrazolopyrimidines and substituted purines and their use as ubiquitin-specific-processing protease 1 (usp1) inhibitors |
| US20240182481A1 (en) | 2021-02-15 | 2024-06-06 | Tango Therapeutics, Inc. | Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer |
-
2019
- 2019-12-19 WO PCT/US2019/067521 patent/WO2020132269A1/en unknown
- 2019-12-19 KR KR1020217017482A patent/KR20210105887A/ko unknown
- 2019-12-19 EP EP19897934.6A patent/EP3897652A4/en active Pending
- 2019-12-19 CA CA3122108A patent/CA3122108A1/en active Pending
- 2019-12-19 CN CN201980079551.2A patent/CN113164485A/zh active Pending
- 2019-12-19 MX MX2021007179A patent/MX2021007179A/es unknown
- 2019-12-19 JP JP2021531985A patent/JP2022511515A/ja active Pending
- 2019-12-19 US US16/721,079 patent/US11485736B2/en active Active
- 2019-12-19 AU AU2019405925A patent/AU2019405925A1/en active Pending
- 2019-12-19 TW TW108146728A patent/TWI834784B/zh active
- 2019-12-19 TW TW113105437A patent/TW202421630A/zh unknown
- 2019-12-19 SG SG11202106232TA patent/SG11202106232TA/en unknown
- 2019-12-19 BR BR112021010715A patent/BR112021010715A2/pt unknown
-
2021
- 2021-06-15 IL IL284050A patent/IL284050A/he unknown
- 2021-06-16 CL CL2021001575A patent/CL2021001575A1/es unknown
- 2021-07-12 CO CONC2021/0009078A patent/CO2021009078A2/es unknown
-
2022
- 2022-10-11 US US18/045,770 patent/US11787813B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021009078A2 (es) | 2021-10-29 |
| JP2022511515A (ja) | 2022-01-31 |
| CL2021001575A1 (es) | 2022-06-03 |
| EP3897652A1 (en) | 2021-10-27 |
| AU2019405925A1 (en) | 2021-07-29 |
| MX2021007179A (es) | 2021-09-28 |
| US20210115049A1 (en) | 2021-04-22 |
| US11485736B2 (en) | 2022-11-01 |
| TW202039501A (zh) | 2020-11-01 |
| US20230203046A1 (en) | 2023-06-29 |
| US11787813B2 (en) | 2023-10-17 |
| CA3122108A1 (en) | 2020-06-25 |
| CN113164485A (zh) | 2021-07-23 |
| BR112021010715A2 (pt) | 2021-11-16 |
| EP3897652A4 (en) | 2022-09-14 |
| KR20210105887A (ko) | 2021-08-27 |
| TWI834784B (zh) | 2024-03-11 |
| WO2020132269A1 (en) | 2020-06-25 |
| SG11202106232TA (en) | 2021-07-29 |
| TW202421630A (zh) | 2024-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284050A (he) | פיראזולופירימידינים מותמרים ופורינים מותמרים והשימוש בהם כמעכבי 1 uso | |
| IL282487A (he) | מעכבים מסוג tyk2 והשימוש בהם | |
| IL288381A (he) | מעכבי tead ושימושים בהם | |
| IL288384A (he) | מעכבי tead ושימושים בהם | |
| IL272910A (he) | מעכבי אקטונוקלאוטיד פירופוספאט-פוספודיאסטראז 1 (enpp-1) ושימושים שלהם | |
| SG11202010636VA (en) | Solid forms of an fgfr inhibitor and processes for preparing the same | |
| IL283409A (he) | מעכבי tyk2 ושימושים בהם | |
| IL282090A (he) | מעכבי tyk2 ושימושים בהם | |
| ZA202106511B (en) | Jak inhibitor compound and use thereof | |
| IL286248A (he) | מעכבי tyk2 והשימוש בהם | |
| IL284799A (he) | מעכבי tyk2 ושימושים בהם | |
| IL279475A (he) | מעכבי אקטונוקליאוטידאז ושיטות לשימוש בהם | |
| EP3572400C0 (en) | EZH2 INHIBITOR AND ITS USE | |
| IL272649B (he) | מעכבי ahr ושימושים בהם | |
| IL282350A (he) | מעכבים ברנני-rgmc ושימוש בהם | |
| SG11202008925VA (en) | Inhibitors of micro-rna 22 | |
| IL285595A (he) | מעכבים של spt5 ושימוש בהם | |
| ZA202004909B (en) | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (usp19) | |
| ZA202102192B (en) | Fgfr4 inhibitor and use thereof | |
| IL279276A (he) | מעכב erk ושימוש בו | |
| IL286485A (he) | מעכבי pi4-קיינאס ושיטות לשימוש בהן | |
| IL274737A (he) | תולדות פיפרידיניל חדשות כמעכבים של פרוטיאז 7 ספציפי לאוביקוויטין | |
| IL283706A (he) | חומרים פרמאצבטים ושימושם כמעכבים של פרוטיאז 19 ספציפי של אוביקוויטין | |
| IL283106A (he) | מעכבי erk ושימושים בהם | |
| EP3756689A4 (en) | INHIBITORS OF IL-17A ACTIVITY AND USE THEREOF |